



2021 US LIFE INSURANCE PRICING SURVEY DEEP DIVE

SEAC Annual Meeting: November 2021

CONFIDENTIALITY

Our clients' industries are extremely competitive, and the maintenance of confidentiality with respect to our clients' plans and data is critical. Oliver Wyman rigorously applies internal confidentiality practices to protect the confidentiality of all client information.

Similarly, our industry is very competitive. We view our approaches and insights as proprietary and therefore look to our clients to protect our interests in our proposals, presentations, methodologies, and analytical techniques. Under no circumstances should this material be shared with any third party without the prior written consent of Oliver Wyman.

REPORT CONTENTS

Product overview




5

2 Pricing methodology and assumptions



12

SURVEY BASIS FOR RESULTS AND CONFIDENTIALITY




PRODUCT OVERVIEW



UNIVERSAL LIFE (UL)


More participants reported UL products exceeding expectations and fewer reported products falling short of expectations this year. Investment returns continue to be the primary driver of performance.





INDEXED UNIVERSAL LIFE (IUL)


Compared to last year, the number of IUL carriers who noted that profitability fell short of expectations halved with the vast majority of participants noting the profits meet expectations. Investment returns continue to be the primary driver of performance.





VARIABLE UNIVERSAL LIFE (VUL)


Target returns decreased this year and continue to be lower than for other equity-based products due to the primary sources of returns (fees and mortality margin). The portion of writers with protection-oriented designs increased by 10% compared to last year, as writers look to equity performance to help offset the cost of long-term guarantees.





TERM


The term market is highly competitive and target returns are low as market participants seek to achieve underwriting margins in retail channels. Realized returns and target profitability are consistent with last year.





WHOLE LIFE


Whole life target returns are low due to the product's simplicity and stability. Distribution methods are diverse, with target markets ranging from the terminally ill to those seeking fixed-income exposure in their investment portfolio. Profit targets and performance are consistent with last year, despite fewer reports of reinsurance benefiting pricing.





COLI/BOLI

COLI/BOLI pricing targets and performance are better than last year, with all participants' products performing at or above target




PRICING METHODOLOGY AND ASSUMPTIONS



UNIVERSAL LIFE

Sensitivity testing is a common approach to reflect risk in UL pricing and is even more prevalent for UL products with secondary guarantees; lengthy pricing horizons are driven by the long tail of the liability. Perhaps driven by pressured earnings, nearly 20% of participants moved to the use of marginal expenses.




¹Structured assets (e.g., CLO, CMBS, RMBS, ABS), high yield, traditional risky assets (e.g., real estate, equities) other risky assets (e.g., alternative, private equity, hedge funds, venture capital, debt financing)



INDEXED UNIVERSAL LIFE

Pricing assumptions and methodology are similar to UL, with the exceptions being higher capital targets and more frequent use of stochastic analysis. 10% of IUL writers extended their pricing horizons to above 50 years relative to last year and a similar increase was observed in the portion of writers utilizing tail profit metrics.




¹Structured assets (e.g., CLO, CMBS, RMBS, ABS), high yield, traditional risky assets (e.g., real estate, equities) other risky assets (e.g., alternative, private equity, hedge funds, venture capital, debt financing)



VARIABLE UNIVERSAL LIFE

Pricing assumptions and methodology are similar to UL & IUL. Perhaps driven by the trend toward secondary guarantees, the use of tail profit metrics tripled as compared to last year.




¹Structured assets (e.g., CLO, CMBS, RMBS, ABS), high yield, traditional risky assets (e.g., real estate, equities) other risky assets (e.g., alternative, private equity, hedge funds, venture capital, debt financing)



TERM

Sensitivity testing is relied on by almost all participants to reflect risk in pricing. Compared to last year, 10% more writers are now pricing based on level term + PLT. Use of marginal expenses continues to be at the high end relative to other product types.




¹Structured assets (e.g., CLO, CMBS, RMBS, ABS), high yield, traditional risky assets (e.g., real estate, equities) other risky assets (e.g., alternative, private equity, hedge funds, venture capital, debt financing)



WHOLE LIFE

Pricing assumptions and methodologies are similar to other retail life products. The use of marginal expenses is more common for WL than other lifetime products (UL, IUL, VUL).




¹Structured assets (e.g., CLO, CMBS, RMBS, ABS), high yield, traditional risky assets (e.g., real estate, equities) other risky assets (e.g., alternative, private equity, hedge funds, venture capital, debt financing)



COLI/BOLI

Commensurate with bettering market conditions, a majority of writers are pricing their COLI/BOLI offerings on a new money basis, whereas portfolio rate was most common in last years survey




¹Structured assets (e.g., CLO, CMBS, RMBS, ABS), high yield, traditional risky assets (e.g., real estate, equities) other risky assets (e.g., alternative, private equity, hedge funds, venture capital, debt financing)



DEEP DIVE | EXPENSES (RETAIL PRODUCTS)


Assumptions of long-term expense improvement are slightly more common for health (LTC & ID) products; use of fully allocated expenses most common for annuity products (a reversal from last year)





DEEP DIVE | MORTALITY IMPROVEMENT (RETAIL PRODUCTS)

Results are fairly consistent with prior years, with future mortality improvement assumed by a majority of participants for all product types except for individual disability





DEEP DIVE | PROFIT MONITORING, RATE SETTING, RE-PRICING (RETAIL PRODUCTS)

While a majority of participants monitor their profitability throughout the year for all product types, annuities tend to require more frequent repricing with a vast majority of IVA writers re-pricing their products at least quarterly



QUALIFICATIONS, ASSUMPTIONS, AND LIMITING CONDITIONS

This report is for the exclusive use of the Oliver Wyman client named herein. This report is not intended for general circulation or publication, nor is it to be reproduced, quoted, or distributed for any purpose without the prior written permission of Oliver Wyman. There are no third-party beneficiaries with respect to this report, and Oliver Wyman does not accept any liability to any third party.

Information furnished by others, upon which all or portions of this report are based, is believed to be reliable but has not been independently verified, unless otherwise expressly indicated. Public information and industry and statistical data are from sources we deem to be reliable; however, we make no representation as to the accuracy or completeness of such information. The findings contained in this report may contain predictions based on current data and historical trends. Any such predictions are subject to inherent risks and uncertainties. Oliver Wyman accepts no responsibility for actual results or future events.

The opinions expressed in this report are valid only for the purpose stated herein and as of the date of this report. No obligation is assumed to revise this report to reflect changes, events, or conditions, which occur subsequent to the date hereof.

All decisions in connection with the implementation or use of advice or recommendations contained in this report are the sole responsibility of the client. This report does not represent investment advice nor does it provide an opinion regarding the fairness of any transaction to any and all parties. In addition, this report does not represent legal, medical, accounting, safety, or other specialized advice. For any such advice, Oliver Wyman recommends seeking and obtaining advice from a qualified professional.

